News
Market and company headlines
ABBVAll
Loading
16:00Oct 241 Story
15:00-21:00Oct 232 Stories
AbbVie (ABBV) Stock Gets Fair Value Bump After Analyst Target Increases
AbbVie’s analyst narrative has shifted again, with fair value in one model now set at US$284.79 compared with US$278.61 previously, and other price targets clustering in a wide US$260 to US$325 range. Recent commentary links these higher targets to confidence in AbbVie’s portfolio across immunology, neuroscience and oncology, while still flagging risks around specific programs and crowded positioning. As you read on, you will see how to interpret these moving targets and track the story as it...
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease (CD)iv. Patients now have the option to start SKYRIZI treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment.
10:00-12:00Oct 233 Stories
AbbVie Receives FDA Approval For Its Subcutaneous Induction Regimen For SKYRIZI To Treat Moderately To Severely Active Crohn's Disease
AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?
Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and debt remain key risks.
Goldman Sachs Maintains Neutral on AbbVie, Raises Price Target to $294
09:00Oct 231 Story
17:00-21:00Oct 222 Stories
12:00-14:00Oct 222 Stories
MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”
Key TakeawaysMoonLake shares jumped 18% today after AbbVie reported Phase 3 results for a rival hidradenitis suppurativa drug. AbbVie’s lutikizumab beat placebo by 8 percentage points on its main goal, a result RBC Capital called underwhelming.
Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says
Avalo Therapeutics' (AVTX) abdakibart remains promising for hidradenitis suppurativa, with phase 2 r
08:00-10:00Oct 222 Stories
AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin (IL) 1α/1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint and 8 ranked secondary endpoints.
AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?
The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
05:00Oct 221 Story
11:00-17:00Oct 212 Stories
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw AbbVie (ABBV) settling at $284.8, representing a -1.48% change from its previous close.
AbbVie vs. AstraZeneca: Which Pharma Giant Has the Stronger Earnings Growth Story?
AbbVie Inc. (NYSE:ABBV) and AstraZeneca PLC (NYSE:AZN) are both delivering earnings growth, but their latest results reveal different strengths. AbbVie is benefiting from rapid expansion in its immunology franchise, while AstraZeneca is generating considerable momentum from oncology and rare-disease treatments. According to Yahoo Finance’s latest available valuation snapshots, AbbVie trades at 16.39 times forward earnings, […]
07:00-10:00Oct 213 Stories
AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?
AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.
AbbVie races into F1 as pharma companies continue push into sport
AbbVie is just one of several pharmaceutical companies to pen sponsorship deals in sport, blurring the commercial line between the two industries.
AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian Cancer
AbbVie is pleased to announce that negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully been completed for ELAHERE® (mirvetuximab soravtansine for injection), and that a Letter of Intent (LOI) has been signed by both parties.
03:00-05:00Oct 212 Stories
Barclays Maintains Overweight on AbbVie, Raises Price Target to $325
Barclays analyst Emily Field maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $300 to $325.
Abbvie Signs ELAHERE Reimbursement LoI With The Pan-Canadian Pharmaceutical Alliance
Ovarian cancer is the leading cause of death from gynecological cancers in Canada.1 In 2026, an estimated 3,000 individuals were diagnosed. Most are diagnosed at an advanced stage, and many eventually develop
12:00-18:00Oct 202 Stories
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.
Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says
Spyre Therapeutics' (SYRE) combination therapy approach for inflammatory bowel disease gained furthe
07:00-10:00Oct 202 Stories
Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher
Rapport Therapeutics stock shot higher Tuesday on promising, but mixed, test results for its bipolar treatment.
AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
AbbVie (NYSE: ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team. At the center of the partnership is AbbVie Race to Innovate, a multi-year, purpose-driven campaign, built on a shared belief that innovation is never finished.
03:00Oct 201 Story
11:00-00:00Oct 192 Stories
AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial. Here’s What It Means for a Stock Up 24% in 2026
Key Stats for AbbVie StockCurrent Price: $282. 68Target Price (Mid): ~$367Street Target: ~$283Potential Total Return: ~30%Annualized IRR: ~6% / yearWhat Happened?AbbVie (ABBV) presented primary Phase 2a results for ABBV-466, its investigational two-drug Crohn’s disease combination, at a gastroenterology meeting in Barcelona on October 19.
AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO Readouts
AbbVie (NYSE:ABBV) reported new Phase 2a data for ABBV-466 in Crohn's disease at recent major medical meetings. The dual-targeting ABBV-466 therapy produced higher endoscopic remission rates than single-pathway treatments in the Phase 2a study. Management flagged multiple new and updated presentations on its solid tumor pipeline for the 2026 ESMO Congress. The ABBV-466 Crohn's data and upcoming oncology results only capture part of what investors may want to assess on AbbVie today. Take a...
08:00-10:00Oct 192 Stories
AbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying?
AbbVie Inc. (NYSE:ABBV) and Bristol-Myers Squibb Company (NYSE:BMY) are navigating a familiar pharmaceutical challenge, which revolves around replacing revenue from established medicines with newer products. Despite that broad similarity, investors are valuing their progress very differently. According to Yahoo Finance’s valuation data, AbbVie trades at 16.39 times forward earnings, compared with just 9.36 times for […]
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.
00:00-05:00Oct 192 Stories
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease
AbbVie (NYSE: ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remissiona at Week 12 than either monotherapy in patients with Crohn's disease (CD). The difference in endoscopic remissiona rates between ABBV-466 and monotherapy groups further increased at Week 24. The findings are from the TARGET-CD study, an ongoing open-label, treat-through, Phase 2a platform study in patients wit
AbbVie’s Dual-Target Drug Shows Phase 2 Results for Hard-to-Treat Crohn’s Disease
AbbVie (NYSE:ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remissiona at Week 12 than either
22:00-00:00Oct 182 Stories
Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW
20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ®
Reported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients
New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation
05:00-09:00Oct 172 Stories
AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?
AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding shares for income, consider what the pending Apogee deal and lingering debt load could mean for the payout's future.
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
Rising rates can expose dividend traps, but this Dividend King is built to keep paying.
01:00Oct 171 Story
14:00-18:00Oct 162 Stories
13:00Oct 162 Stories
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?
Pfizer Inc. (NYSE:PFE) trades at a considerable discount to AbbVie Inc. (NYSE:ABBV), despite both companies reporting growth in important parts of their pharmaceutical portfolios. According to Yahoo Finance’s September 23, 2026 valuation snapshot, Pfizer trades at 9.67 times forward earnings, compared with AbbVie’s 16.39 times. That makes Pfizer cheaper on a forward P/E basis, but […]
AbbVie vs. Merck: Which Pharma Stock Offers Better Value?
AbbVie Inc. (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) have something important in common that is important for investors, which is that both must demonstrate that newer medicines can sustain earnings as their established blockbusters face competition. However, the companies are at different stages of that transition, creating an interesting valuation dilemma. According to Yahoo […]
09:00-12:00Oct 162 Stories
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
AbbVie Inc. (NYSE:ABBV) is delivering strong returns this year, with shares surging by over 23% year-to-date. In comparison, the broader market has returned nearly 13% in the same period. Yahoo Finance’s latest data puts AbbVie’s forward P/E at 16.39x, which is considerably different from the company’s trailing P/E of 74.88 because AbbVie’s reported earnings have […]
Trade Tracker: Kevin Simpson buys AbbVie
Kevin Simpson, founder and CEO of Capital Wealth Planning, joins CNBC's 'Halftime Report' to detail his latest portfolio move. The Investment Committee shares their top healthcare plays.
18:00-20:00Oct 152 Stories
AbbVie (ABBV) Stock Could Be 44% Undervalued As Cancer Trial News Lands
AbbVie has delivered strong share price gains in recent years, and the latest drug updates keep the story in the spotlight. The key issue for anyone looking at the stock today is whether that rally is still grounded in the cash it can generate. With the Discounted Cash Flow (DCF) lens in focus, the question is how the current price lines up with the stream of cash flows investors expect AbbVie to produce over time. AbbVie has returned 211.2% over the past 5 years, which puts real weight on...
What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
AbbVie (NYSE:ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 results for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The EPCORE DLBCL-2 study showed a statistically significant reduction in the risk of disease progression or death versus R-CHOP alone. Trial data point to clinically meaningful efficacy in a first line setting for high risk diffuse large B cell lymphoma patients. Epcoritamab plus R-CHOP is only one piece of the story for AbbVie as the oncology pipeline...
10:00-12:00Oct 152 Stories
AbbVie’s Q3 2026 Earnings: What to Expect
Biopharma giant AbbVie is set to report its Q3 results on Oct. 30.
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.
11:00-14:00Oct 142 Stories
Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today.
Shares of Lilly, the world’s largest pharmaceutical company by market value, rallied above their 50-day moving average to mark their best level since August.
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.
08:00-10:00Oct 142 Stories
Did SKYRIZI’s Subcutaneous Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?
Earlier this week, AbbVie reported Phase 3 AFFIRM data showing subcutaneous SKYRIZI induced endoscopic remission and ulcer-free endoscopy in a meaningful share of adults with moderately to severely active Crohn’s disease, with safety consistent with its existing profile. The findings, presented at the 2026 American College of Gastroenterology meeting, could support regulatory reviews of a more convenient subcutaneous induction option and deepen AbbVie’s presence in difficult-to-treat...
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
06:00-23:00Oct 32 Stories
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
AbbVie Inc. (NYSE:ABBV) closed at $262.82 on October 2, and Bristol Myers Squibb Company (NYSE:BMY) at $61.15. Both spent the last few years doing the same difficult thing. Replacing a drug that was about to lose its patent with something new, before the revenue disappeared. AbbVie is widely seen as having pulled it off and […]
AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.
Another potential blockbuster just joined AbbVie's drug portfolio.
09:00-12:00Oct 22 Stories
AbbVie To Participate In Federal 340b Rebate Model Pilot
https://news.abbvie.com/2026-10-02-AbbVie-to-Participate-in-Federal-340B-Rebate-Model-Pilot
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.
13:00-19:00Oct 12 Stories
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.
AbbVie (ABBV) Stock May Be 41% Undervalued Following JUVMO Approval
AbbVie has delivered a powerful 187.5% total return over the past 5 years, so the current US$261.59 share price naturally raises a question for investors who care about cash generation. With fresh drug approvals, pipeline updates and new partnerships in the headlines, the key issue now is whether AbbVie’s cash flows are strong enough and durable enough to underpin where the stock trades today. That 187.5% 5 year return puts real pressure on the valuation question, because a move of that size...
08:00-11:00Oct 12 Stories
AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial and total body repigmentation through week 76.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.